Sign In
Buy ARGX
$813.14
+10.97 (+1.37%)
At Close: Jun 03, 2026
argenx: Priority Review Voucher Goes To Waste And Why SC Efgartigimod Is Important
01:10pm, Monday, 06'th Feb 2023
argenx pre-announced strong Q4 net sales of Vyvgart in early January. The PDUFA date for subcutaneous efgartigimod was pushed back by three months, which means the $98 million Priority Review voucher
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
06:00am, Friday, 27'th Jan 2023 GlobeNewswire Inc.
January 27, 2023
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
06:30pm, Monday, 16'th Jan 2023 GlobeNewswire Inc.
January 16, 2023
Immunocore Holdings PLC Sponsored ADR (IMCR) Soars 6.9%: Is Further Upside Left in the Stock?
09:41am, Friday, 13'th Jan 2023 Zacks Investment Research
Immunocore Holdings PLC Sponsored ADR (IMCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest
Halozyme (HALO) Down 9.2% on Weak 2023 Financial Guidance
02:47pm, Thursday, 12'th Jan 2023 Zacks Investment Research
Though Halozyme (HALO) expects a year-over-year increase in revenues and earnings for 2023, the company's guidance fell short of Wall Street expectations.
argenex SE (ARGX) Upgraded to Buy: What Does It Mean for the Stock?
05:00pm, Tuesday, 10'th Jan 2023 Zacks Investment Research
argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Analyst Ratings for argenx
02:01pm, Tuesday, 10'th Jan 2023 Benzinga
argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
4
3
0
0
0
Last 30D
1
0
0
AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday
01:48pm, Tuesday, 10'th Jan 2023 Benzinga
Keybanc boosted Five Below, Inc. (NASDAQ: FIVE) price target from $188 to $200. Keybanc analyst Bradley Thomas maintained an Overweight rating on the stock. Five Below shares fell 1.6% to $183.92 i
argenex SE (ARGX) Upgraded to Buy: What Does It Mean for the Stock?
01:32pm, Tuesday, 10'th Jan 2023
argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
06:00am, Monday, 09'th Jan 2023 GlobeNewswire Inc.
Reported $402 million in preliminary* full-year 2022 global net VYVGART sales
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
06:00am, Tuesday, 03'rd Jan 2023 GlobeNewswire Inc.
January 3, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
01:00am, Tuesday, 03'rd Jan 2023
January 3 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, to
100 Best Stocks Of 2022: Oil Stocks And Medicals Shine
06:00pm, Friday, 30'th Dec 2022
Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business
Alphabet To $115? Here Are 10 Other Price Target Changes For Thursday
01:33pm, Thursday, 22'nd Dec 2022 Benzinga
Stifel raised argenx SE (NASDAQ: ARGX) price target from $471 to $478. Stifel analyst Alex Thompson maintained a Buy rating on the stock. argenx shares rose 1.1% to $387.07 in pre-market trading.
argenx Appoints Ana Cespedes to Board of Directors
09:01pm, Monday, 12'th Dec 2022 GlobeNewswire Inc.
December 12, 2022
